The National Health Surveillance Agency (Anvisa) announced on Tuesday (23) the authorization to register the vaccine of Pfizer / Biontech against Covid-19. The federal government is still negotiating the purchase of the immunizer with the pharmaceutical company.
Anvisa’s CEO, Antonio Barra Torres, said that the vaccine produced by the Pfizer / Biontech laboratory had the safety, quality and efficacy necessary for the approval of the immunizers.
“As Chief Executive Officer of the National Health Surveillance Agency, I inform you with great satisfaction that, after a seventeen-day review period, the General Management of Medicines, of the Second Board, granted the first vaccine registration against Covid 19, for in the Americas “, said in a statement published by Anvisa.
Anvisa is the first reference authority by the Pan American Health Organization (PAHO) to grant registration of a vaccine from Covid-19, with seven certified manufacturing sites.
“The immunizer from the Pfizer / Biontech Laboratory had its safety, quality and efficacy, assessed and certified by the technical team of Anvisa servers that continues in its work to protect the health of the Brazilian citizen”.
Barra Torres also said that he hopes that “other vaccines are soon being evaluated and approved. That is our commitment.”
The vaccines produced by the Chinese laboratory Sinovac, in partnership with the Butantan Institute, and that of the pharmaceutical company Astrazeneca, developed in collaboration with the University of Oxford and under contracts with the Oswaldo Cruz Foundation (Fiocruz), are authorized for emergency use in Brazil – without definitive record.
News in update.